CEO presents Pearsanta IPO plans; commercialization target Q1 2026

Aditxt, Inc.

CEO Amro Albanna presented at Wall Street Reporter livestream; discussed Pearsanta IPO plans.
Pearsanta's cancer diagnostics platform uses mitochondrial DNA blood tests; initial targets prostate cancer and endometriosis.
Commercial launch of first tests targeted for end of 2025 / Q1 2026 after validation studies.
Pearsanta IPO planned for early first half 2026 with Spartan Capital as underwriter.
Aditxt strategy: acquire health innovations, build in-house, monetize via events like Pearsanta IPO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.